Justices Won't Review Fed. Circ. Ruling Axing Drug Dosing IP
The U.S. Supreme Court said Monday it won't look at a Federal Circuit decision invalidating a Baxter Corp. telepharmacy patent that survived inter partes review, leaving undecided the company's argument that...To view the full article, register now.
Already a subscriber? Click here to view full article